Crossmark

Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor–tyrosine kinase inhibitor resistance subclones

Crossref DOI link: https://doi.org/10.1038/s12276-025-01493-2

Published Online: 2025-07-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, Namhee

Hwang, Mihwa

Ahn, Beung Chul

Lee, Youngjoo

Hong, Sehwa

Sim, Hanna

Song, Bo Ram

Kim, Sunshin

Park, Charny https://orcid.org/0000-0001-5857-7695
Han, Ji-Youn
Funding

Funding for this research was provided by:

National Cancer Center (NCC-2510840, NCC-2210550, NCC-2210550, NCC-2210550)

National Research Foundation of Korea (NRF-2022R1A2C1005708, RS-2023-00273744, NRF-2023R1A2C2003565)

Korea Health Industry Development Institute (HI21C0416010021)
License Information

Text and Data Mining valid from 2025-07-04

Version of Record valid from 2025-07-04
More Information

Article History

Received: 13 November 2024

Revised: 5 March 2025

Accepted: 23 April 2025

First Online: 4 July 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below